-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team recently, Paige announced that the US FDA has granted its artificial intelligence (AI) prostate cancer diagnostic system Paige Prostate marketing authorization
.
Paige Prostate is a clinical-level AI solution that can help pathologists understand prostate cancer pathological tissue slices and find potential cancer lesions
.
Studies have shown that the number of global cancer cases is expected to increase by 60% in the next two decades.
However, relative to this diagnostic demand, the number of pathologists is far from enough, so there is an urgent need to provide new technologies for pathology practice
.
Paige Prostate, as a new type of AI cancer diagnosis solution, can identify suspicious cancer lesions and provide this information to pathologists
.
It aims to help pathologists find small lesions and improve diagnosis efficiency
.
The clinical trial data submitted to the FDA showed that pathologists using Paige Prostate increased their sensitivity in correctly diagnosing cancer by more than 7 percentage points, from 89.
5% to 96.
8%, false negative diagnoses decreased by 70%, and false positive diagnoses A reduction of 24%
.
Moreover, this improvement has nothing to do with the pathologist's years of experience, and whether the analysis is done remotely or on-site
.
In addition, the data also shows that non-specialist pathologists who use Paige Prostate are as accurate as prostate cancer specialists who do not use the software
.
The company plans to submit complete data for publication in peer-reviewed journals
.
▲Paige Prostate is used to discover potential prostate cancer lesions (picture source: reference [1]) "The US FDA's approval of Paige Prostate marks a new era in computer-aided diagnosis for pathology
.
This innovation is a lot of future.
The introduction of the tool has paved the way and will help standardize pathological diagnosis and speed up the diagnosis process
.
" Paige’s co-founder and chief medical officer, Dr.
David Klimstra, said, "The US FDA’s approval allows pathology laboratories to introduce this diagnostic tool.
Its clinical workflow, which will allow pathologists to focus on the most critical aspects of determining the diagnosis
.
"Reference: [1] Paige Receives First Ever FDA Approval for AI Product in Digital Pathology.
Retrieved September 22, 2021, from https:// Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
Paige Prostate is a clinical-level AI solution that can help pathologists understand prostate cancer pathological tissue slices and find potential cancer lesions
.
Studies have shown that the number of global cancer cases is expected to increase by 60% in the next two decades.
However, relative to this diagnostic demand, the number of pathologists is far from enough, so there is an urgent need to provide new technologies for pathology practice
.
Paige Prostate, as a new type of AI cancer diagnosis solution, can identify suspicious cancer lesions and provide this information to pathologists
.
It aims to help pathologists find small lesions and improve diagnosis efficiency
.
The clinical trial data submitted to the FDA showed that pathologists using Paige Prostate increased their sensitivity in correctly diagnosing cancer by more than 7 percentage points, from 89.
5% to 96.
8%, false negative diagnoses decreased by 70%, and false positive diagnoses A reduction of 24%
.
Moreover, this improvement has nothing to do with the pathologist's years of experience, and whether the analysis is done remotely or on-site
.
In addition, the data also shows that non-specialist pathologists who use Paige Prostate are as accurate as prostate cancer specialists who do not use the software
.
The company plans to submit complete data for publication in peer-reviewed journals
.
▲Paige Prostate is used to discover potential prostate cancer lesions (picture source: reference [1]) "The US FDA's approval of Paige Prostate marks a new era in computer-aided diagnosis for pathology
.
This innovation is a lot of future.
The introduction of the tool has paved the way and will help standardize pathological diagnosis and speed up the diagnosis process
.
" Paige’s co-founder and chief medical officer, Dr.
David Klimstra, said, "The US FDA’s approval allows pathology laboratories to introduce this diagnostic tool.
Its clinical workflow, which will allow pathologists to focus on the most critical aspects of determining the diagnosis
.
"Reference: [1] Paige Receives First Ever FDA Approval for AI Product in Digital Pathology.
Retrieved September 22, 2021, from https:// Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
